Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine Company anticipates new data set to bolster existing compelling data reported to date, including efficacy outcomes more than double the benchmarks* Outcomes also expected to identify recommended Phase 2 dose APVO436 renamed as mipletamig: Aptevo adopts new generic name for future use SEATTLE, WA / ACCESSWIRE / August 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIRâ„¢ and ADAPTIR-FLEXâ„¢ platform technologies, today, announced initiation of the Company's Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate APVO436 in combination with venetoclax + azacitidine for frontline patients with acute myeloid leukemia (AML). RAINIER will be conducted in two parts.
Frontline Plc's Stock And Fleet Are On The Upswing
Frontline plc stock is rated as a buy-to-strong buy opportunity after a recent drop in share price. Growth opportunities in the marine shipping industry outweigh risks, with demand for crude tankers expected to remain high in the coming years. Frontline plc has a high dividend yield of 10.9% and strong financial metrics, despite accumulating debt to finance its fleet of tankers.
Buy alert: 2 high-yield dividend stocks with ‘Strong Buy' rating for July 2024
The Fed's anticipated rate cut could make high-yield stocks more attractive compared to bonds. When interest rates fall, existing bonds become less appealing, potentially leading investors towards higher-yielding equities.
Hot Stocks: 3 Untapped Opportunities for a 1,000% Return
Finding high-return stock opportunities in the market may transform investors' lives. Here, the exploration focuses on three unexplored stock possibilities that might yield remarkable returns of up to 1,000%.
Frontline's Aggressive Acquisition Strategy Pays Off Amid Global Disruptions
Frontline reported strong earnings and distributions, indicating a positive outlook for the company. The company's fleet consists of VLCCs, Suezmaxes, and LR2 tankers, with a focus on fuel efficiency and scrubber-fitted vessels. The war in Ukraine and disruptions in the Suez Canal are expected to continue to impact rates.
Frontline plc (FRO) Q1 2024 Earnings Call Transcript
Frontline plc (NYSE:FRO ) Q1 2024 Earnings Conference Call May 30, 2024 9:00 AM ET Company Participants Lars Barstad - Chief Executive Officer Inger Klemp - Chief Financial Officer Conference Call Participants Omar Nokta - Jefferies Gregory Lewis - BTIG Petter Haugen - ABG Sundal Collier Lars Barstad Dear, all. Thank you for dialing in to Frontline's First Quarter Earnings Call.
Is a Beat in Store for Frontline (FRO) in Q1 Earnings?
Frontline's (FRO) Q1 performance is expected to be affected by supply-chain disruptions.
Although Frontline Is Up 83% In 1 Year, We Think There Is More To Come
We examine earnings potential from the acquisition of 24 modern VLCCs from Euronav. The gearing ratio is expected to increase from 62% to 65% in Q1 2024. Favorable supply and demand dynamics over the next two to three years support higher earnings for VLCC.
